Yedan Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yedan Ren has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Junfen Xu
Department of Gynecologic Oncology, Women's Hospital Zhejiang University School of Medicine Hangzhou China
3 shared publications - Xiuli Zhang
Department of Gynecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications - Ling Wang
Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang, China
1 shared publication - Sen Li
Women's Reproductive Health Laboratory of Zhejiang Province, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China
1 shared publication - Simin Xiang
Department of Gynecology and Oncology Women's Hospital, Zhejiang University School of Medicine Zhejiang Hangzhou China
1 shared publication - Yaxia Chen
Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, Zhejiang, China.
1 shared publication
Latest Publications
- Open Access
- 11 July 2026
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Ectocervical margin involvement is associated with postoperative hrHPV positivity after hysterectomy or residual cervix resection for incompletely excised CIN3: a retrospective study
Persistent high-risk human papillomavirus (hrHPV) infection after hysterectomy or residual cervix resection for incompletely excised cervical intraepitheli
- 11 July 2026
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Open AccessEctocervical margin involvement is associated with postoperative hrHPV positivity after hysterectomy or residual cervix resection for incompletely excised CIN3: a retrospective study
Persistent high-risk human papillomavirus (hrHPV) infection after hysterectomy or residual cervix resection for incompletely excised cervical intraepitheli
- Open Access
- 10 June 2026
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1)
Clinical outcomes of a 3-day modified BEP regimen in malignant ovarian germ cell tumors in a single-center real-world study
Malignant ovarian germ cell tumors (MOGCTs) mainly affect adolescents and young women and are highly curable with bleomycin, etoposide, and cisplatin (BEP). To reduce toxicity associated with the standard 5-day regimen, we evaluated the efficacy, safety, and fertility outcomes of a 3-day modified BEP regimen in patients with MOGCTs. We conducted a retrospective analysis of 81 MOGCT patients with 3-day modified BEP at the Women's Hospital, Zhejiang University School of Medicine from 2004 to 2024. The 3-day modified BEP regimen comprised bleomycin (15 U) and etoposide (100 mg/m2) on days 1-3, and cisplatin (75 mg/m2) on day 1, repeated every 4 weeks for 3-6 cycles. All 81 MOGCT patients included in our study underwent primary surgery before chemotherapy; 86.4% had early-stage disease, and fertility-sparing surgery was performed in 73 cases. After a median follow-up of over 9 years, the 5-year progression-free survival rate was 97.5% (95% CI: 94.2-100), with no treatment-related deaths. Bleomycin-induced pneumonitis occurred in 4.9% and resolved with supportive care. Among 30 patients attempting conception, 90% achieved pregnancy, resulting in 25 term live births. The 3-day modified BEP regimen provides excellent survival with reduced toxicity, offering greater convenience and preserved fertility, supporting its use as a safer and more practical treatment alternative for initial chemotherapy in MOGCTs.
- 10 June 2026
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1)
Open AccessClinical outcomes of a 3-day modified BEP regimen in malignant ovarian germ cell tumors in a single-center real-world study
Malignant ovarian germ cell tumors (MOGCTs) mainly affect adolescents and young women and are highly curable with bleomycin, etoposide, and cisplatin (BEP). To reduce toxicity associated with the standard 5-day regimen, we evaluated the efficacy, safety, and fertility outcomes of a 3-day modified BEP regimen in patients with MOGCTs. We conducted a retrospective analysis of 81 MOGCT patients with 3-day modified BEP at the Women's Hospital, Zhejiang University School of Medicine from 2004 to 2024. The 3-day modified BEP regimen comprised bleomycin (15 U) and etoposide (100 mg/m2) on days 1-3, and cisplatin (75 mg/m2) on day 1, repeated every 4 weeks for 3-6 cycles. All 81 MOGCT patients included in our study underwent primary surgery before chemotherapy; 86.4% had early-stage disease, and fertility-sparing surgery was performed in 73 cases. After a median follow-up of over 9 years, the 5-year progression-free survival rate was 97.5% (95% CI: 94.2-100), with no treatment-related deaths. Bleomycin-induced pneumonitis occurred in 4.9% and resolved with supportive care. Among 30 patients attempting conception, 90% achieved pregnancy, resulting in 25 term live births. The 3-day modified BEP regimen provides excellent survival with reduced toxicity, offering greater convenience and preserved fertility, supporting its use as a safer and more practical treatment alternative for initial chemotherapy in MOGCTs.
- Open Access
- 31 December 2025
- Published by Wiley in Cancer Medicine
- Vol. 15 (1) , e71488
A Retrospective Study on the Clinicopathological Characteristics and Prognostic Analysis of Gynecologic Neuroendocrine Carcinoma
Background: Gynecologic neuroendocrine carcinomas (NECs) are rare, highly aggressive malignancies with early metastatic potential and limited evidence to guide optimal management across different primary sites. Aims: To characterize the clinicopathological features, treatment patterns, survival outcomes, and prognostic factors of gynecologic NECs (cervix, endometrium, and ovary) treated at a single tertiary center over a 10‐year period. Materials and Methods: This observational, single‐center retrospective cohort study included patients diagnosed with gynecologic NEC at Women's Hospital, Zhejiang University School of Medicine, between January 2013 and August 2023. Clinicopathological data, treatment modalities, recurrence, and follow‐up outcomes were collected. Progression‐free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods. Prognostic factors were assessed using log‐rank tests and multivariable Cox proportional hazards models. Results: A total of 52 patients were identified, of whom 78.8% had cervical NEC. Primary surgery was performed in 90.4% of patients; adjuvant chemotherapy and radiotherapy were administered in 65.4% and 51.9%, respectively. Among cervical NEC cases with HPV testing, 69.7% were HPV16/18‐positive. Immunohistochemical (IHC) showed high positivity for synaptophysin (95.3%) and chromogranin A (72.7%); Ki‐67 exceeded 50% in 89.1% of evaluated cases. Median PFS for cervical NEC was 29 months; stage I cervical NEC showed a 5‐year PFS of 51.6% and 5‐year OS of 68.4%. Poorer prognosis was associated with FIGO stage ≥ IB3, mixed neuroendocrine‐non‐neuroendocrine neoplasm (MiNEN) with squamous cell carcinoma, tumor size > 4 cm, and lymph node metastasis. On multivariable analysis of cervical NEC, MiNEN with squamous cell carcinoma remained an independent predictor of reduced PFS (HR = 6.97, 95% CI: 1.60–30.31; p = 0.010). Discussion: Despite multimodal treatment, gynecologic NECs showed poor outcomes. The identification of MiNEN with squamous cell carcinoma as an independent adverse factor for PFS suggests histologic composition may meaningfully affect prognosis and warrants validation in larger, multicenter cohorts. Conclusion: Cervical NEC was the predominant subtype, most patients underwent surgery with adjuvant therapy, and survival was strongly stage‐dependent. MiNEN with squamous cell carcinoma independently predicted worse PFS, highlighting a potential high‐risk subgroup and reinforcing the need for multicenter prospective studies and more effective, potentially targeted treatment approaches for gynecologic NECs.
- 31 December 2025
- Published by Wiley in Cancer Medicine
- Vol. 15 (1) , e71488
Open AccessA Retrospective Study on the Clinicopathological Characteristics and Prognostic Analysis of Gynecologic Neuroendocrine Carcinoma
Background: Gynecologic neuroendocrine carcinomas (NECs) are rare, highly aggressive malignancies with early metastatic potential and limited evidence to guide optimal management across different primary sites. Aims: To characterize the clinicopathological features, treatment patterns, survival outcomes, and prognostic factors of gynecologic NECs (cervix, endometrium, and ovary) treated at a single tertiary center over a 10‐year period. Materials and Methods: This observational, single‐center retrospective cohort study included patients diagnosed with gynecologic NEC at Women's Hospital, Zhejiang University School of Medicine, between January 2013 and August 2023. Clinicopathological data, treatment modalities, recurrence, and follow‐up outcomes were collected. Progression‐free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods. Prognostic factors were assessed using log‐rank tests and multivariable Cox proportional hazards models. Results: A total of 52 patients were identified, of whom 78.8% had cervical NEC. Primary surgery was performed in 90.4% of patients; adjuvant chemotherapy and radiotherapy were administered in 65.4% and 51.9%, respectively. Among cervical NEC cases with HPV testing, 69.7% were HPV16/18‐positive. Immunohistochemical (IHC) showed high positivity for synaptophysin (95.3%) and chromogranin A (72.7%); Ki‐67 exceeded 50% in 89.1% of evaluated cases. Median PFS for cervical NEC was 29 months; stage I cervical NEC showed a 5‐year PFS of 51.6% and 5‐year OS of 68.4%. Poorer prognosis was associated with FIGO stage ≥ IB3, mixed neuroendocrine‐non‐neuroendocrine neoplasm (MiNEN) with squamous cell carcinoma, tumor size > 4 cm, and lymph node metastasis. On multivariable analysis of cervical NEC, MiNEN with squamous cell carcinoma remained an independent predictor of reduced PFS (HR = 6.97, 95% CI: 1.60–30.31; p = 0.010). Discussion: Despite multimodal treatment, gynecologic NECs showed poor outcomes. The identification of MiNEN with squamous cell carcinoma as an independent adverse factor for PFS suggests histologic composition may meaningfully affect prognosis and warrants validation in larger, multicenter cohorts. Conclusion: Cervical NEC was the predominant subtype, most patients underwent surgery with adjuvant therapy, and survival was strongly stage‐dependent. MiNEN with squamous cell carcinoma independently predicted worse PFS, highlighting a potential high‐risk subgroup and reinforcing the need for multicenter prospective studies and more effective, potentially targeted treatment approaches for gynecologic NECs.